本研究旨在探讨血清肿瘤M2-丙酮酸激酶（TuM2-PK）、神经元特异性烯醇酸酯酶（NSE）和前胃泌素释放肽（ProGRP）水平对小细胞肺癌（SCLC）患者的诊断和预后价值。检测了102例SCLC患者、60例良性肺疾病（BLD）患者和90例健康对照组的血清TuM2-PK、NSE和ProGRP水平。结果显示，SCLC组的血清TuM2-PK、NSE和ProGRP水平高于BLD组（p<0.05）和健康对照组（p<0.05）。TuM2-PK、NSE和ProGRP检测对SCLC的敏感性分别为82.35％、60.78％和77.45％，特异性分别为91.11％、81.11％和86.67％。TuM2-PK导致的SCLC曲线下面积（AUC）显着优于NSE和ProGRP。应用TuM2-PK联合NSE和ProGRP可以提高SCLC患者的诊断率，且具有比单独使用TuM2-PK更好的诊断价值。单因素和多因素分析表明，TuM2-PK水平升高是SCLC患者短期存活的独立预后因素。这些结果表明，血清中的TuM2-PK水平可以是SCLC诊断和预后的有效生物标志物。© 2023 The Authors. 由Wiley Periodicals LLC出版的《临床实验室分析期刊》。

The aim of this study was to explore the diagnostic and prognostic value of serum tumor M2-pyruvate kinase (TuM2-PK), neuron-specific enolase (NSE), and progastrin-releasing peptide (ProGRP) levels in patients with small cell lung cancer (SCLC).The levels of serum TuM2-PK, NSE, and ProGRP in 102 patients with SCLC, 60 patients with benign lung disease (BLD), and 90 healthy controls were detected.The serum TuM2-PK, NSE, and ProGRP levels in the SCLC group were higher than those in BLD group (p < 0.05) and healthy control group (p < 0.05). The sensitivity of TuM2-PK, NSE, and ProGRP detection in SCLC was 82.35%, 60.78%, and 77.45% respectively, and specificity was 91.11%, 81.11%, and 86.67%, respectively. The area under the curve (AUC) of SCLC resulting from TuM2-PK was significantly better than that of NSE and ProGRP. The application of TuM2-PK combined with NSE and ProGRP improved the diagnostic yield of SCLC patients and had better diagnostic value than TuM2-PK alone. Univariate and multivariate analysis indicated that an elevated TuM2-PK level was an independent prognostic factor for shorter survival in SCLC.These results suggest that TuM2-PK levels in the serum could be an effective biomarker for the diagnosis and prognosis of SCLC.© 2023 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.